Instagram Outage Disrupts Thousands of U.S. Users 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
JERSEY, Channel Islands, May 09, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the UBS Global Healthcare Conference on Tuesday, May 23, 2017 at 10:30 a.m. Eastern Time at the Grand Hyatt New York. Also participating in the conference will be the Company’s Chief Financial Officer, Chris Lindop.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
